
Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label Options for MAUD
0:00
10:07
In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking?
Faculty: David Gorelick, M.D.
Host: Richard Seeber, M.D.
Otros episodios de "Psychopharmacology and Psychiatry Updates"
No te pierdas ningún episodio de “Psychopharmacology and Psychiatry Updates”. Síguelo en la aplicación gratuita de GetPodcast.